Next Article in Journal
Nanosecond Pulsed Electric Fields Induce Endoplasmic Reticulum Stress Accompanied by Immunogenic Cell Death in Murine Models of Lymphoma and Colorectal Cancer
Next Article in Special Issue
A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells
Previous Article in Journal
Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Previous Article in Special Issue
Direct Targeting Options for STAT3 and STAT5 in Cancer
Open AccessReview

Companion Animals as Models for Inhibition of STAT3 and STAT5

Division of Small Animal Internal Medicine, Department of Companion Animals and Horses, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(12), 2035; https://doi.org/10.3390/cancers11122035
Received: 6 November 2019 / Revised: 12 December 2019 / Accepted: 13 December 2019 / Published: 17 December 2019
(This article belongs to the Special Issue Targeting STAT3 and STAT5 in Cancer)
The use of transgenic mouse models has revolutionized the study of many human diseases. However, murine models are limited in their representation of spontaneously arising tumors and often lack key clinical signs and pathological changes. Thus, a closer representation of complex human diseases is of high therapeutic relevance. Given the high failure rate of drugs at the clinical trial phase (i.e., around 90%), there is a critical need for additional clinically relevant animal models. Companion animals like cats and dogs display chronic inflammatory or neoplastic diseases that closely resemble the human counterpart. Cat and dog patients can also be treated with clinically approved inhibitors or, if ethics and drug safety studies allow, pilot studies can be conducted using, e.g., inhibitors of the evolutionary conserved JAK-STAT pathway. The incidence by which different types of cancers occur in companion animals as well as mechanisms of disease are unique between humans and companion animals, where one can learn from each other. Taking advantage of this situation, existing inhibitors of known oncogenic STAT3/5 or JAK kinase signaling pathways can be studied in the context of rare human diseases, benefitting both, the development of drugs for human use and their application in veterinary medicine. View Full-Text
Keywords: cancer models; companion animals; STAT3; STAT5; comparative oncology cancer models; companion animals; STAT3; STAT5; comparative oncology
Show Figures

Figure 1

MDPI and ACS Style

Kieslinger, M.; Swoboda, A.; Kramer, N.; Pratscher, B.; Wolfesberger, B.; Burgener, I.A. Companion Animals as Models for Inhibition of STAT3 and STAT5. Cancers 2019, 11, 2035. https://doi.org/10.3390/cancers11122035

AMA Style

Kieslinger M, Swoboda A, Kramer N, Pratscher B, Wolfesberger B, Burgener IA. Companion Animals as Models for Inhibition of STAT3 and STAT5. Cancers. 2019; 11(12):2035. https://doi.org/10.3390/cancers11122035

Chicago/Turabian Style

Kieslinger, Matthias; Swoboda, Alexander; Kramer, Nina; Pratscher, Barbara; Wolfesberger, Birgitt; Burgener, Iwan A. 2019. "Companion Animals as Models for Inhibition of STAT3 and STAT5" Cancers 11, no. 12: 2035. https://doi.org/10.3390/cancers11122035

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop